» Articles » PMID: 32953328

Nosocomial Achromobacter Xylosoxidans Infection Presenting As a Cavitary Lung Lesion in a Lung Cancer Patient

Overview
Journal Cureus
Date 2020 Sep 21
PMID 32953328
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

is a Gram-negative bacillus that is known to cause nosocomial infections, primarily in patients with hematological malignancies. The most common primary manifestation is bacteremia. We report a novel case of primary infection presenting as a cavitary lung lesion with associated pneumonia in a lung cancer patient who showed no evidence of malignant disease progression after radiation therapy. Our patient was initially admitted for acute hypoxic respiratory failure requiring mechanical ventilation. Initial computed tomography (CT) revealed a cavitary lesion in the right upper lobe of the lung. Diagnostic bronchoscopy with bronchoalveolar lavage (BAL) was performed and was negative for infectious etiologies including tuberculosis (TB) and fungal infections. Cytology was also negative for malignancy. However, the bacterial culture grew . Antimicrobial therapy was initiated based on culture susceptibilities and the patient showed significant improvement in oxygen requirements. Due to poor functional status, the palliative care route was pursued and mechanical ventilation weaning was not performed. Cavitary pulmonary infections secondary to are rarely reported in the medical literature. After conducting a thorough PubMed database search of the medical literature, we believe this is the first case of infection manifesting as a cavitary lung lesion with associated pneumonia in a lung cancer patient.

Citing Articles

Achromobacter xylosoxidans Purulent Bronchitis in a Previously Healthy Child: An Unexpected Consequence of COVID-19 Infection.

Matijasic N, Tripalo Batos A, Lenicek Krleza J, Rogulj M, Pavic I Cureus. 2022; 14(1):e21711.

PMID: 35242477 PMC: 8884523. DOI: 10.7759/cureus.21711.


Evaluation of the Whole Proteome of to Identify Vaccine Targets for mRNA and Peptides-Based Vaccine Designing Against the Emerging Respiratory and Lung Cancer-Causing Bacteria.

Khan T, Abdullah M, Toor T, Almajhdi F, Suleman M, Iqbal A Front Med (Lausanne). 2022; 8:825876.

PMID: 35186980 PMC: 8854494. DOI: 10.3389/fmed.2021.825876.


Retraction: a case of meningitis due to in a child with a polymalformative syndrome: a case report.

Pan Afr Med J. 2021; 40:89.

PMID: 34707772 PMC: 8514459. DOI: 10.11604/pamj.2021.40.89.31949.

References
1.
van Hasselt J, Rizk M, Lala M, Chavez-Eng C, Visser S, Kerbusch T . Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid. Br J Clin Pharmacol. 2016; 81(6):1113-23. PMC: 4876184. DOI: 10.1111/bcp.12901. View

2.
Kikuchi T, Mori T, Kohashi S, Yamane Y, Okayama M, Mashima E . [Cellulitis due to Achromobacter xylosoxidans during bortezomib therapy for multiple myeloma]. Rinsho Ketsueki. 2016; 57(2):175-9. DOI: 10.11406/rinketsu.57.175. View

3.
Sammassimo S, Pruneri G, Andreola G, Montoro J, Steffanoni S, Nowakowski G . A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG). Hematol Oncol. 2015; 34(4):177-183. DOI: 10.1002/hon.2243. View

4.
Claassen S, Reese J, Mysliwiec V, Mahlen S . Achromobacter xylosoxidans infection presenting as a pulmonary nodule mimicking cancer. J Clin Microbiol. 2011; 49(7):2751-4. PMC: 3147868. DOI: 10.1128/JCM.02571-10. View

5.
Perez Barragan E, Sandino Perez J, Corbella L, Orellana M, Fernandez-Ruiz M . Achromobacter xylosoxidans bacteremia: clinical and microbiological features in a 10-year case series. Rev Esp Quimioter. 2018; 31(3):268-273. PMC: 6166261. View